Pancreatic Cancer Research

ResearcherUniversity of Bari Aldo MoroActive in the last 2 years

Tiago M. A. Carvalho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9095-1413; OpenAlex author ID A5035460175. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/apha.70183↗
  2. Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemc… Co-author DOI 10.3390/cells13090730↗
  3. Increased demand for FAD synthesis in differentiated and stem pancreatic cancer cells is accomplished by modulating FLAD1 gene expression: the inhibitory effec… First author DOI 10.1111/febs.16881↗
  4. Acidic Growth Conditions Promote Epithelial-to-Mesenchymal Transition to Select More Aggressive PDAC Cell Phenotypes In Vitro. First author DOI 10.3390/cancers15092572↗
  5. Extracellular Matrix Collagen I Differentially Regulates the Metabolic Plasticity of Pancreatic Ductal Adenocarcinoma Parenchymal Cell and Cancer Stem Cell. Co-author DOI 10.3390/cancers15153868↗
  6. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Co-author DOI 10.3390/cancers14102486↗
  7. Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition. Co-author DOI 10.3390/cancers14153737↗
  8. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as The… Co-author DOI 10.3390/cancers13236135↗
  9. Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer. Co-author DOI 10.3390/ijms22083953↗
  10. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine. Co-author DOI 10.3390/ijms22010029↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephan J. Reshkin · 10 shared papers, 2020–2026 · strength 1.64
  2. Rosa Angela Cardone · 10 shared papers, 2020–2026 · strength 1.64
  3. Maria Raffaella Greco · 6 shared papers, 2020–2024 · strength 0.94
  4. Tomas Koltai · 4 shared papers, 2021–2024 · strength 0.70
  5. Natalia B. Prevarskaya · 3 shared papers, 2023–2026 · strength 0.53
  6. Madelaine Magalì Audero · 3 shared papers, 2023–2026 · strength 0.53
  7. Alessandra Fiorio Pla · 3 shared papers, 2023–2026 · strength 0.53
  8. Albrecht Schwab · 2 shared papers, 2023–2026 · strength 0.34
  9. Stefania Cannone · 2 shared papers, 2022–2023 · strength 0.34
  10. Silvia Arpicco · 2 shared papers, 2020–2024 · strength 0.28
  11. Pawel Swietach · 1 shared paper, 2026 · strength 0.19
  12. Sofie Hagelund · 1 shared paper, 2026 · strength 0.19
  13. Verena Hofschröer · 1 shared paper, 2026 · strength 0.19
  14. Laura Mezzanotte · 1 shared paper, 2026 · strength 0.19
  15. Zoltán Pethő · 1 shared paper, 2026 · strength 0.19
  16. Torsten Hechler · 1 shared paper, 2026 · strength 0.19
  17. Julie Schnipper · 1 shared paper, 2026 · strength 0.19
  18. Wiktoria Błaszczak · 1 shared paper, 2026 · strength 0.19
  19. Frauke Alves · 1 shared paper, 2026 · strength 0.19
  20. Ganga Deshar · 1 shared paper, 2026 · strength 0.19
  21. Ivana Novak · 1 shared paper, 2026 · strength 0.19
  22. Renata Ialchina · 1 shared paper, 2026 · strength 0.19
  23. Luis A. Pardo · 1 shared paper, 2026 · strength 0.19
  24. Roisin McMorrow · 1 shared paper, 2026 · strength 0.19
  25. Anna Trauzold · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.